
Please try another search
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company’s clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
James Bruce Tananbaum | 61 | - | Independent Director |
Martin Babler | 59 | 2021 | President, CEO & Chairman |
Zhengbin Yao | 59 | 2021 | Independent Director |
C. Patrick Machado | 60 | 2024 | Independent Director |
Srinivas Akkaraju | 56 | 2024 | Independent Director |
Alan B. Colowick | 62 | 2022 | Independent Director |
Lynn A. Tetrault | 62 | 2025 | Independent Director |
Sapna Srivastava | 54 | 2022 | Lead Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review